^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD9 inhibitor

    Related drugs:
    11d
    Study of KBA1412 in Participants With Advanced Solid Malignant Tumors (clinicaltrials.gov)
    P1, N=16, Completed, Kling Biotherapeutics B.V. | Recruiting --> Completed | N=106 --> 16 | Trial completion date: Jan 2025 --> Jul 2024 | Trial primary completion date: Jan 2025 --> Jul 2024
    Trial completion • Enrollment change • Trial completion date • Trial primary completion date • Combination therapy • Metastases
    |
    Keytruda (pembrolizumab) • KBA1412
    over3years
    CD9 inhibition reveals a functional connection of extracellular vesicle secretion with mitophagy in melanoma cells. (PubMed, J Extracell Vesicles)
    CD9 KO cells were able to compensate the mitochondrial malfunction by increasing total mitochondrial mass reducing mitophagy. Our data thus provide the first evidence for a functional connection of tetraspanin CD9 with mitophagy in melanoma cells.
    Journal
    |
    CD9 (CD9 Molecule)
    almost4years
    Tetraspanin CD9 interacts with α-secretase to enhance its oncogenic function in pancreatic cancer. (PubMed, Am J Transl Res)
    Finally, CD9 antibody showed anti-tumor effects in cell proliferation MTT assay, transwell migration assay and colony formation assay. Our study reveals a novel CD9/ADAM/Notch signaling network in PDAC and it supports that targeting CD9-ADAM interaction with antibody may be a potential therapeutic intervention for PDAC.
    Journal
    |
    ADAM9 (ADAM Metallopeptidase Domain 9) • CD9 (CD9 Molecule)
    |
    CD9 expression
    4years
    [VIRTUAL] AT1412, a patient-derived CD9 antibody promotes tumour immune infiltration and induces tumour rejection (ESMO 2020)
    In a second melanoma model carrying a PD-1 resistant and highly aggressive tumour (SK-MEL5) AT1412 together with nivolumab was inducing full tumour rejection, while either one of the antibodies alone did not. Legal entity responsible for the study: The authors. Funding: AIMM Therapeutics.
    Clinical
    |
    CD8 (cluster of differentiation 8) • CD9 (CD9 Molecule)
    |
    Opdivo (nivolumab) • AT1412